Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | CCNC | P24863 | 6/20 | 0.43 |
| ▸ | CDK8 | P49336 | 6/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MYLK | Q15746 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | CILK1 | Q9UPZ9 | 1/20 | 0.43 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17207643 | 0.81 | TAS2R8 (0.44) | CYP11B2CCNCCDK8AURKBTAS2R8 | |
| SCHEMBL10044956 | 0.78 | ALPI (0.50) | CYP11B2CCNCCDK8FLT3MYLK | |
| SCHEMBL18508505 | 0.77 | TYK2 (0.43) | FLT3TAS2R8PDK2JAK3JAK2 | |
| SCHEMBL1703729 | 0.77 | CCNC (0.45) | CCNCCDK8FLT3MYLKAURKB | |
| SCHEMBL12492720 | 0.77 | CCNC (0.45) | CYP11B2CCNCCDK8FLT3MYLK | |
| SCHEMBL17605207 | 0.77 | CCNC (0.47) | CYP11B2CCNCCDK8FLT3MYLK | |
| SCHEMBL22236775 | 0.76 | CYP11B2 (0.60) | CYP11B2 | |
| SCHEMBL12020134 | 0.75 | CCNC (0.44) | CCNCCDK8FLT3MYLKAURKB | |
| SCHEMBL16472361 | 0.75 | CCNC (0.46) | CCNCCDK8FLT3MYLKAURKB | |
| SCHEMBL26005634 | 0.75 | CCNC (0.44) | CYP11B2CCNCCDK8FLT3MYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | CYP11B2 19/4885CCNC 2386/4885CDK8 2180/4885 |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | CYP11B2 17/4885CCNC 2256/4885CDK8 2035/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | CYP11B2 19/4885CCNC 2386/4885CDK8 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.